Showing 1 - 7 results of 7 for search 'Blerina Resuli', query time: 0.02s Refine Results
  1. 1
    Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature

    Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature by Blerina Resuli, Blerina Resuli, Heidi Galarza, Heidi Galarza, Diego Kauffmann-Guerrero, Diego Kauffmann-Guerrero, Julian Oversohl, Julian Oversohl, Jürgen Behr, Jürgen Behr, Amanda Tufman, Amanda Tufman

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports

    Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports by Blerina Resuli, MD, Diego Kauffmann-Guerrero, MD, Jürgen Behr, MD, Amanda Tufman, MD

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Safety of brigatinib following alectinib-induced-pneumonitis: Case report

    Safety of brigatinib following alectinib-induced-pneumonitis: Case report by Blerina Resuli, Heidi Galarza, Laura Elsner, Diego Kauffmann-Guerrero, Jürgen Behr, Amanda Tufman

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Treatment Strategies for First-Line PD-L1-Unselected Advanced NSCLC: A Comparative Review of Immunotherapy-Based Regimens by PD-L1 Expression and Clinical Indication

    Treatment Strategies for First-Line PD-L1-Unselected Advanced NSCLC: A Comparative Review of Immunotherapy-Based Regimens by PD-L1 Expression and Clinical Indication by Blerina Resuli, Diego Kauffmann-Guerrero, Maria Nieves Arredondo Lasso, Jürgen Behr, Amanda Tufman

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Changes in prescribing patterns and access to immune checkpoint inhibitors in german lung cancer patients – a claims data analysis

    Changes in prescribing patterns and access to immune checkpoint inhibitors in german lung cancer patients – a claims data analysis by Julia Walter, Blerina Resuli, Laura Sellmer, Diego Kauffmann-Guerrero, Toki Bolt, Chukwuka Eze, Jürgen Behr, Amanda Tufman

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Elevated FDG uptake in non-tumorous lung regions does not predict immune checkpoint inhibitor–related pneumonitis in lung cancer patients

    Elevated FDG uptake in non-tumorous lung regions does not predict immune checkpoint inhibitor–related pneumonitis in lung cancer patients by Friederike Völter, Friederike Völter, Friederike Völter, Lukas Wehlte, Blerina Resuli, Blerina Resuli, Blerina Resuli, Julia Walter, Julia Walter, Julia Walter, Lea Daisenberger, Maria Ingenerf, Maurice Heimer, Matthias Brendel, Matthias Brendel, Matthias Brendel, Gabriel T. Sheikh, Lena M. Unterrainer, Lena M. Unterrainer, Lena M. Unterrainer, Diego Kauffmann-Guerrero, Diego Kauffmann-Guerrero, Diego Kauffmann-Guerrero, Thomas Pfluger, Lucie Heinzerling, Lucie Heinzerling, Amanda Tufman, Amanda Tufman, Amanda Tufman

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Toxicity Profile and Efficacy of Docetaxel Following Paclitaxel- or Pemetrexed-Platinum Chemotherapy Alone or in Combination With Immune Checkpoint Inhibitors in NSCLC Patients: A Single Institution Retrospective Analysis

    Toxicity Profile and Efficacy of Docetaxel Following Paclitaxel- or Pemetrexed-Platinum Chemotherapy Alone or in Combination With Immune Checkpoint Inhibitors in NSCLC Patients: A... by Blerina Resuli MD, Julia Walter, Diego Kauffmann-Guerrero MD, Pontus Mertsch MD, Maria Arredondo Lasso, Paola Arnold MD, Christian Schneider MD, Jürgen Behr MD, Amanda Tufman MD

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: